Trial Title:
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
NCT ID:
NCT05554380
Condition:
Locally Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm
Conditions: Official terms:
Neoplasms
Paclitaxel
Albumin-Bound Paclitaxel
Ipatasertib
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Procedure
Intervention name:
Biopsy
Description:
Undergo tumor biopsy
Arm group label:
Treatment (paclitaxel, ipatasertib)
Other name:
BIOPSY_TYPE
Other name:
Bx
Intervention type:
Procedure
Intervention name:
Biospecimen Collection
Description:
Undergo blood collection
Arm group label:
Treatment (paclitaxel, ipatasertib)
Other name:
Biological Sample Collection
Other name:
Biospecimen Collected
Other name:
Specimen Collection
Intervention type:
Procedure
Intervention name:
Computed Tomography
Description:
Undergo CT scan
Arm group label:
Treatment (paclitaxel, ipatasertib)
Other name:
CAT
Other name:
CAT Scan
Other name:
Computed Axial Tomography
Other name:
Computerized Axial Tomography
Other name:
Computerized axial tomography (procedure)
Other name:
Computerized Tomography
Other name:
Computerized Tomography (CT) scan
Other name:
CT
Other name:
CT Scan
Other name:
tomography
Intervention type:
Drug
Intervention name:
Ipatasertib
Description:
Given PO
Arm group label:
Treatment (paclitaxel, ipatasertib)
Other name:
GDC 0068
Other name:
GDC-0068
Other name:
GDC0068
Other name:
RG 7440
Other name:
RG-7440
Other name:
RG7440
Intervention type:
Procedure
Intervention name:
Magnetic Resonance Imaging
Description:
Undergo MRI
Arm group label:
Treatment (paclitaxel, ipatasertib)
Other name:
Magnetic Resonance
Other name:
Magnetic Resonance Imaging (MRI)
Other name:
Magnetic resonance imaging (procedure)
Other name:
Magnetic Resonance Imaging Scan
Other name:
Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
Other name:
MR
Other name:
MR Imaging
Other name:
MRI
Other name:
MRI Scan
Other name:
MRIs
Other name:
NMR Imaging
Other name:
NMRI
Other name:
Nuclear Magnetic Resonance Imaging
Other name:
sMRI
Other name:
Structural MRI
Intervention type:
Drug
Intervention name:
Paclitaxel
Description:
Given IV
Arm group label:
Treatment (paclitaxel, ipatasertib)
Other name:
Anzatax
Other name:
Asotax
Other name:
Bristaxol
Other name:
Praxel
Other name:
Taxol
Other name:
Taxol Konzentrat
Summary:
This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy
(paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be
removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally
advanced) or from where it first started (primary site) to other places in the body
(metastatic), and has PTEN and AKT genetic changes. Chemotherapy drugs, such as
paclitaxel, work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Targeted
therapy, such as Ipatasertib, may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. The addition of ipatasertib to paclitaxel in solid tumors
with PTEN and AKT genetic changes could increase the percentage of tumors that shrink as
well as lengthen the time that the tumors remain stable (without progression).
Researchers hope to learn if paclitaxel plus ipatasertib will shrink this type of cancer
or stop its growth.
Detailed description:
PRIMARY OBJECTIVE:
I. To assess the overall response rate (ORR) (confirmed and unconfirmed, complete, and
partial) with the combination of paclitaxel plus ipatasertib in participants with
advanced PTEN/AKT-altered non-breast solid tumors who have previously progressed on
taxane-based therapy
SECONDARY OBJECTIVES:
I. To assess the progression-free survival (PFS) in the study population. II. To assess
the duration of response (DoR) in participants who respond to treatment.
III. To assess the overall survival (OS) in the study population. IV. To evaluate the
frequency and severity of toxicities related to the combination therapy.
V. Collect tissue and provide it to the ComboMATCH Registration protocol to assess
concordance between the diagnostic tumor mutation profile generated by the designated
laboratories, the pre-treatment biopsy mutation profile, and the pre-treatment
circulating tumor deoxyribonucleic acid (ctDNA) mutation profile from plasma, as
described in ComboMATCH Registration protocol. For this treatment substudy, the outcome
objective will be to report the proportion of cases providing sufficient tissue for that
integrated scientific activity in the ComboMATCH Registration protocol.
TRANSLATIONAL MEDICINE OBJECTIVES:
I. To conduct whole exome sequencing (WES) and ribonucleic acid (RNA) sequencing (RNAseq)
analysis of tumors at baseline (mandatory), as well as PTEN expression analysis of tumors
at baseline (2nd priority after nucleic acid for WES and RNAseq).
II. To explore changes in plasma PTEN/AKT mutation allelic burden and other molecular
findings at baseline (mandatory) and upon progression (optional) using ctDNA and
correlate changes with response/resistance to therapy.
III. To perform comprehensive protein expression and function analysis on fresh frozen
specimens (optional) collected at baseline and at progression to assess determinants of
response and resistance to therapy.
OUTLINE:
Patients receive paclitaxel intravenously (IV) on days 1, 8, and 15 and ipatasertib
orally (PO) on days 1-21. Treatment repeats every 28 days for up to 35 cycles in the
absence of disease progression or unacceptable toxicity. Patients undergo a computed
tomography (CT) or magnetic resonance imaging (MRI) and blood collection throughout the
trial. Patients also undergo a tumor biopsy during screening and follow-up.
After completion of study treatment, patients are followed until death or 3 years after
registration, whichever occurs first.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Patient must have enrolled onto EAY191 and must have been given a treatment
assignment to ComboMATCH to EAY191-S3 based on the presence of an actionable
mutation as defined in EAY191
- GENERAL COMBOMATCH EAY191 REGISTRATION INCLUSION CRITERIA:
- Participants must be enrolled on the ComboMATCH Master Registration Trial EAY191
- Participants must have an activating AKT mutation (a known mutation in AKT1, AKT2,
or AKT3, a single nucleotide variant, insertion, or deletion), PTEN mutation (a
known mutation in PTEN, a single nucleotide variant, insertion, or deletion), or
genomic deletion loss of PTEN as determined by the ComboMATCH screening assessment
- GENERAL COMBOMATCH EAY191 REGISTRATION EXCLUSION CRITERIA:
- Participants must not have an activating KRAS, NRAS, HRAS, or BRAF mutation (a
single nucleotide variant, insertion, or deletion) as determined by the ComboMATCH
screening assessment
- Participants must have disease that can be safely biopsied and agree to a
pre-treatment biopsy or have archival tissue available from within 12 months prior
to the date of registration on the ComboMATCH Registration Trial (EAY191)
- Participants must have a histologically confirmed non-breast solid malignancy
- Participants must have locally advanced, unresectable, or metastatic disease in the
opinion of the treating investigator
- Participants must have measurable disease documented by CT or MRI. Measurable
disease must be assessed within 28 days prior to registration. Non-measurable
disease must be assessed within 42 days prior to registration. The CT from a
combined positron emission tomography (PET)/CT may be used only if it is of
diagnostic quality. All known sites of disease must be assessed and documented on
the Baseline Tumor Assessment Form (Response Evaluation Criteria in Solid Tumors
[RECIST] 1.1). Participants whose only measurable disease is within a previous
radiation therapy port must demonstrate clearly progressive disease (in the opinion
of the treating investigator) prior to registration
- Participants with known brain metastases must have a CT/MRI scan to evaluate for
central nervous system (CNS) disease and show no evidence of progression within 42
days prior to registration
- Participants must have completed any CNS-directed therapy and/or local therapy for
spinal cord compression at least 28 days prior to registration
- Participants must not have spinal cord compression or brain metastases unless: (1)
metastases have been locally treated and have remained clinically controlled and
asymptomatic for at least 14 days prior to registration, AND (2) participant has no
residual neurological dysfunction and has been off corticosteroids for at least 24
hours prior to registration
- Participants must not have leptomeningeal disease
- Participants must have progressed on or within 6 months of taxane-based therapy in
the neoadjuvant/adjuvant or metastatic setting prior to registration
- Participants must not have received any prior AKT inhibitor (e.g., capivasertib or
ipatasertib); prior PI3K/mTOR inhibitor is acceptable
- Participants must not have received cancer-directed therapy prior for at least 14
days prior to initiation of treatment on study
- Participants must not be planning to receive any concurrent chemotherapy,
immunotherapy, biologic, radiation, or hormonal therapy for cancer treatment while
receiving treatment on this study
- Participants must be >= 18 years of age
- Participants must be able to swallow oral medications whole
- Participants must have a pre-study history and physical exam done within 28 days
prior to registration
- Participants must have a Zubrod performance status of 0-2 within 28 days prior to
registration
- Participants must have adverse events resolved =< grade 1 related to any prior
therapy, except alopecia within 14 days prior to registration
- Participants with neuropathy must have resolved to < grade 2 within 14 days prior to
registration
- Leukocytes >= 3 x 10^3/uL (within 28 days prior to registration)
- Absolute neutrophil count >= 1.5 x 10^3/uL (within 28 days prior to registration)
- Platelets >= 100 x 10^3/uL (within 28 days prior to registration)
- Total bilirubin =< institutional upper limit of normal (ULN) unless history of
Gilbert's disease. Participants with history of Gilbert's disease must have total
bilirubin =< 5 x institutional ULN (within 28 days prior to registration)
- Aspartate aminotransferase (AST) & alanine aminotransferase (ALT) =< 3 x
institutional ULN (within 28 days prior to registration)
- Participants must have adequate cardiac function, class IIB (2B) or better.
Participants with known history or current symptoms of cardiac disease, or history
of treatment with cardiotoxic agents, must have a clinical risk assessment of
cardiac function using the New York Heart Association Functional Classification
- Participants must have a measured OR calculated creatinine clearance >= 50 mL/min
using the following Cockcroft-Gault formula. This specimen must have been drawn
within 28 days prior to registration
- Participants with known human immunodeficiency virus (HIV)-infection must be
receiving anti-retroviral therapy and have an undetectable viral load test on the
most recent test results obtained within 6 months prior to registration
- Participants with evidence of chronic hepatitis B virus (HBV) infection must have
undetectable HBV viral load on suppressive therapy within 28 days prior to
registration
- Participants with a history of hepatitis C virus (HCV) infection must have been
treated and cured. Participants with HCV infection who are currently on treatment
must have an undetectable HCV viral load within 28 days prior to registration
- Participants must have an electrocardiography (ECG) performed (if clinically
indicated with a corrected QTc interval of =< 470 msec) within 28 days prior to
registration
- Participants must not have a history of allergic reactions attributed to compounds
of similar chemical or biologic composition to ipatasertib and/or paclitaxel
- Participants must not have an active small/large bowel inflammation such as
ulcerative colitis or Crohn's disease
- Participants must not have grade 2 or higher uncontrolled intercurrent illness
- NOTE: To receive an agent, participant must not have any uncontrolled
intercurrent illness requiring antibiotic/antiviral/antifungal therapy or
interventional procedures. Participants with infections unlikely to be resolved
within 2 weeks following registration should not be considered for the trial
- Participants must not have a known grade 2 or higher uncontrolled or untreated
hypercholesterolemia or hypertriglyceridemia
- Participants must not have any of the following:
- Cirrhosis at a level of Child-Pugh B (or worse),
- Cirrhosis (any degree) and a history of hepatic encephalopathy, or
- Clinically meaningful ascites resulting from cirrhosis. Clinically meaningful
ascites is defined as ascites from cirrhosis requiring diuretics or
paracentesis
- Participants must not be receiving any medications or substances that are inhibitors
or inducers of CYP3A. Treatment with strong CYP3A inhibitors or strong CYP3A
inducers within 2 weeks or 5 drug-elimination half-lives, whichever is longer, prior
to initiation of study drug is prohibited.
- NOTE: Because the lists of these agents are constantly changing, it is
important to regularly consult a frequently updated medical reference. As part
of the enrollment/informed consent procedures, the participant will be
counseled on the risk of interactions with other agents, and what to do if new
medications need to be prescribed or if the participant is considering a new
over-the-counter medicine or herbal product. The participant wallet card should
be presented to the participant
- Participants must not have baseline fasting glucose (after 8-hour fast) > 160 mg/dL
(8.9 mmol/L) within 28 days prior to registration
- Participants with known diabetes mellitus must not require insulin therapy or have a
baseline fasting glucose >150 mg/dL (8.3 mmol/L) or high glycosylated hemoglobin
(Hb)A1c, (>= 8.0%), suggesting poorly controlled diabetes
- Participants who are on a stable dose of oral diabetes medication >= 2 weeks prior
to initiation of study drug treatment are eligible for enrollment
- Participants with a prior or concurrent malignancy whose natural history or
treatment (in the opinion of the treating physician) must not have a potential to
interfere with the safety or efficacy assessment of the investigational regimen
- Participants must not have lung disease requiring active systemic therapy or placing
participants at increased risk of toxicity related to study-directed therapy
including, but not limited to pneumonitis, interstitial lung disease, idiopathic
pulmonary fibrosis, cystic fibrosis, aspergillosis, active tuberculosis, or history
of opportunistic infections (pneumocystis pneumonia or cytomegalovirus pneumonia)
- Participants must not be pregnant or nursing. Individuals who are of reproductive
potential must have agreed to use an effective contraceptive method with details
provided as a part of the consent process. A person who has had menses at any time
in the preceding 12 consecutive months or who has semen likely to contain sperm is
of "reproductive potential". In addition to routine contraceptive methods,
"effective contraception" also includes surgery intended to prevent pregnancy (or
with a side-effect of pregnancy prevention) including hysterectomy, bilateral
oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing
no sperm in the semen
- Participants must not have psychiatric illness/social situations that would limit
compliance with study requirements
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
University of Alabama at Birmingham Cancer Center
Address:
City:
Birmingham
Zip:
35233
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
205-934-0220
Email:
tmyrick@uab.edu
Investigator:
Last name:
Rebecca C. Arend
Email:
Principal Investigator
Facility:
Name:
University of South Alabama Mitchell Cancer Institute
Address:
City:
Mobile
Zip:
36688
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
251-445-9870
Email:
pfrancisco@usouthal.edu
Investigator:
Last name:
Ahmed Abdalla
Email:
Principal Investigator
Facility:
Name:
Kingman Regional Medical Center
Address:
City:
Kingman
Zip:
86401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
PCR Oncology
Address:
City:
Arroyo Grande
Zip:
93420
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
Saint Joseph Hospital - Orange
Address:
City:
Orange
Zip:
92868
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
714-734-6220
Investigator:
Last name:
Timothy E. Byun
Email:
Principal Investigator
Facility:
Name:
Stanford Cancer Institute Palo Alto
Address:
City:
Palo Alto
Zip:
94304
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
650-498-7061
Email:
ccto-office@stanford.edu
Investigator:
Last name:
James M. Ford
Email:
Principal Investigator
Facility:
Name:
Saint John's Cancer Institute
Address:
City:
Santa Monica
Zip:
90404
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
310-582-7448
Investigator:
Last name:
Reva K. Basho
Email:
Principal Investigator
Facility:
Name:
UM Sylvester Comprehensive Cancer Center at Aventura
Address:
City:
Aventura
Zip:
33180
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
954-461-2180
Investigator:
Last name:
Chukwuemeka (Emeka) V. Ikpeazu
Email:
Principal Investigator
Facility:
Name:
UM Sylvester Comprehensive Cancer Center at Coral Gables
Address:
City:
Coral Gables
Zip:
33146
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
305-243-2647
Investigator:
Last name:
Chukwuemeka (Emeka) V. Ikpeazu
Email:
Principal Investigator
Facility:
Name:
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Address:
City:
Deerfield Beach
Zip:
33442
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
305-243-2647
Investigator:
Last name:
Chukwuemeka (Emeka) V. Ikpeazu
Email:
Principal Investigator
Facility:
Name:
Mayo Clinic in Florida
Address:
City:
Jacksonville
Zip:
32224-9980
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
855-776-0015
Investigator:
Last name:
Aaron S. Mansfield
Email:
Principal Investigator
Facility:
Name:
University of Miami Miller School of Medicine-Sylvester Cancer Center
Address:
City:
Miami
Zip:
33136
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
305-243-2647
Investigator:
Last name:
Chukwuemeka (Emeka) V. Ikpeazu
Email:
Principal Investigator
Facility:
Name:
UM Sylvester Comprehensive Cancer Center at Kendall
Address:
City:
Miami
Zip:
33176
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
305-243-2647
Investigator:
Last name:
Chukwuemeka (Emeka) V. Ikpeazu
Email:
Principal Investigator
Facility:
Name:
UM Sylvester Comprehensive Cancer Center at Plantation
Address:
City:
Plantation
Zip:
33324
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
305-243-2647
Investigator:
Last name:
Chukwuemeka (Emeka) V. Ikpeazu
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Boise
Address:
City:
Boise
Zip:
83706
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-3671
Email:
stephanie.couch@stjoeshealth.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Boise
Address:
City:
Boise
Zip:
83712
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Caldwell
Address:
City:
Caldwell
Zip:
83605
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-3671
Email:
stephanie.couch@stjoeshealth.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kootenai Health - Coeur d'Alene
Address:
City:
Coeur d'Alene
Zip:
83814
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Fruitland
Address:
City:
Fruitland
Zip:
83619
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Meridian
Address:
City:
Meridian
Zip:
83642
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Nampa
Address:
City:
Nampa
Zip:
83687
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Nampa
Address:
City:
Nampa
Zip:
83687
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
Kootenai Clinic Cancer Services - Post Falls
Address:
City:
Post Falls
Zip:
83854
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kootenai Clinic Cancer Services - Sandpoint
Address:
City:
Sandpoint
Zip:
83864
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Twin Falls
Address:
City:
Twin Falls
Zip:
83301
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
Advocate Good Shepherd Hospital
Address:
City:
Barrington
Zip:
60010
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
847-842-4847
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
John H Stroger Jr Hospital of Cook County
Address:
City:
Chicago
Zip:
60612
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
312-864-5204
Investigator:
Last name:
Thomas E. Lad
Email:
Principal Investigator
Facility:
Name:
University of Chicago Comprehensive Cancer Center
Address:
City:
Chicago
Zip:
60637
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
773-702-8222
Email:
cancerclinicaltrials@bsd.uchicago.edu
Investigator:
Last name:
Ardaman Shergill
Email:
Principal Investigator
Facility:
Name:
Advocate Illinois Masonic Medical Center
Address:
City:
Chicago
Zip:
60657
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
773-296-5360
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
AMG Crystal Lake - Oncology
Address:
City:
Crystal Lake
Zip:
60014
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-929-6129
Email:
advocateresearch@advocate.com
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Carle at The Riverfront
Address:
City:
Danville
Zip:
61832
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@Carle.com
Investigator:
Last name:
Tanmay Sahai
Email:
Principal Investigator
Facility:
Name:
Advocate Good Samaritan Hospital
Address:
City:
Downers Grove
Zip:
60515
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-275-1270
Email:
Barbara.barhamand@advocatehealth.com
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Carle Physician Group-Effingham
Address:
City:
Effingham
Zip:
62401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Tanmay Sahai
Email:
Principal Investigator
Facility:
Name:
Advocate Sherman Hospital
Address:
City:
Elgin
Zip:
60123
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
847-429-2907
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Advocate South Suburban Hospital
Address:
City:
Hazel Crest
Zip:
60429
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
708-799-9995
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
AMG Libertyville - Oncology
Address:
City:
Libertyville
Zip:
60048
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-929-6129
Email:
advocateresearch@advocatehealth.com
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Condell Memorial Hospital
Address:
City:
Libertyville
Zip:
60048
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-929-6129
Email:
advocateresearch@advocatehealth.com
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Carle Physician Group-Mattoon/Charleston
Address:
City:
Mattoon
Zip:
61938
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Tanmay Sahai
Email:
Principal Investigator
Facility:
Name:
UC Comprehensive Cancer Center at Silver Cross
Address:
City:
New Lenox
Zip:
60451
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
773-702-8222
Email:
cancerclinicaltrials@bsd.uchicago.edu
Investigator:
Last name:
Ardaman Shergill
Email:
Principal Investigator
Facility:
Name:
Advocate Christ Medical Center
Address:
City:
Oak Lawn
Zip:
60453-2699
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-323-8622
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
University of Chicago Medicine-Orland Park
Address:
City:
Orland Park
Zip:
60462
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
773-702-8222
Email:
cancerclinicaltrials@bsd.uchicago.edu
Investigator:
Last name:
Ardaman Shergill
Email:
Principal Investigator
Facility:
Name:
Advocate Lutheran General Hospital
Address:
City:
Park Ridge
Zip:
60068
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
847-384-3621
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Carle Cancer Center
Address:
City:
Urbana
Zip:
61801
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Tanmay Sahai
Email:
Principal Investigator
Facility:
Name:
Mission Cancer and Blood - Ankeny
Address:
City:
Ankeny
Zip:
50023
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-282-2921
Investigator:
Last name:
Richard L. Deming
Email:
Principal Investigator
Facility:
Name:
Mission Cancer and Blood - Des Moines
Address:
City:
Des Moines
Zip:
50309
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-241-3305
Investigator:
Last name:
Seema Harichand-Herdt
Email:
Principal Investigator
Facility:
Name:
Mercy Medical Center - Des Moines
Address:
City:
Des Moines
Zip:
50314
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-358-6613
Email:
cancerresearch@mercydesmoines.org
Investigator:
Last name:
Richard L. Deming
Email:
Principal Investigator
Facility:
Name:
University of Kentucky/Markey Cancer Center
Address:
City:
Lexington
Zip:
40536
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
859-257-3379
Investigator:
Last name:
Susanne M. Arnold
Email:
Principal Investigator
Facility:
Name:
Lafayette Family Cancer Center-EMMC
Address:
City:
Brewer
Zip:
04412
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-987-3005
Investigator:
Last name:
Sarah J. Sinclair
Email:
Principal Investigator
Facility:
Name:
University of Maryland/Greenebaum Cancer Center
Address:
City:
Baltimore
Zip:
21201
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-888-8823
Investigator:
Last name:
Ranee Mehra
Email:
Principal Investigator
Facility:
Name:
National Institutes of Health Clinical Center
Address:
City:
Bethesda
Zip:
20892
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-411-1222
Investigator:
Last name:
A P. Chen
Email:
Principal Investigator
Facility:
Name:
UPMC Western Maryland
Address:
City:
Cumberland
Zip:
21502
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
240-964-1400
Investigator:
Last name:
Haider S. Mahdi
Email:
Principal Investigator
Facility:
Name:
Tufts Medical Center
Address:
City:
Boston
Zip:
02111
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
617-636-5000
Email:
ContactUsCancerCenter@TuftsMedicalCenter.org
Investigator:
Last name:
Katina M. Robison
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Address:
City:
Ann Arbor
Zip:
48106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Address:
City:
Brighton
Zip:
48114
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Medical Center - Brighton
Address:
City:
Brighton
Zip:
48114
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Canton
Address:
City:
Canton
Zip:
48188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Medical Center - Canton
Address:
City:
Canton
Zip:
48188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Chelsea Hospital
Address:
City:
Chelsea
Zip:
48118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Address:
City:
Chelsea
Zip:
48118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Corewell Health Dearborn Hospital
Address:
City:
Dearborn
Zip:
48124
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
Corewell Health Farmington Hills Hospital
Address:
City:
Farmington Hills
Zip:
48336
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
Genesee Cancer and Blood Disease Treatment Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Genesee Hematology Oncology PC
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Genesys Hurley Cancer Institute
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Hurley Medical Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
University of Michigan Health - Sparrow Lansing
Address:
City:
Lansing
Zip:
48912
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
517-364-3712
Email:
harsha.trivedi@umhsparrow.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Mary Mercy Livonia Hospital
Address:
City:
Livonia
Zip:
48154
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Henry Ford Saint John Hospital - Macomb Medical
Address:
City:
Macomb
Zip:
48044
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
kforman1@hfhs.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Corewell Health William Beaumont University Hospital
Address:
City:
Royal Oak
Zip:
48073
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
MyMichigan Medical Center Saginaw
Address:
City:
Saginaw
Zip:
48601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Oncology Hematology Associates of Saginaw Valley PC
Address:
City:
Saginaw
Zip:
48604
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
989-907-8411
Email:
lori.srebinski@ascension.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
MyMichigan Medical Center Tawas
Address:
City:
Tawas City
Zip:
48764
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Corewell Health Beaumont Troy Hospital
Address:
City:
Troy
Zip:
48085
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
Saint Mary's Oncology/Hematology Associates of West Branch
Address:
City:
West Branch
Zip:
48661
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
989-907-8411
Email:
lori.srebinski@ascension.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Huron Gastroenterology PC
Address:
City:
Ypsilanti
Zip:
48106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Address:
City:
Ypsilanti
Zip:
48197
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Sanford Joe Lueken Cancer Center
Address:
City:
Bemidji
Zip:
56601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-333-5000
Email:
OncologyClinicalTrialsFargo@sanfordhealth.org
Investigator:
Last name:
Daniel Almquist
Email:
Principal Investigator
Facility:
Name:
Mercy Hospital
Address:
City:
Coon Rapids
Zip:
55433
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Essentia Health - Deer River Clinic
Address:
City:
Deer River
Zip:
56636
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Essentia Health Cancer Center
Address:
City:
Duluth
Zip:
55805
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Fairview Southdale Hospital
Address:
City:
Edina
Zip:
55435
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Essentia Health Hibbing Clinic
Address:
City:
Hibbing
Zip:
55746
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Abbott-Northwestern Hospital
Address:
City:
Minneapolis
Zip:
55407
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Mayo Clinic in Rochester
Address:
City:
Rochester
Zip:
55905
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
855-776-0015
Investigator:
Last name:
Aaron S. Mansfield
Email:
Principal Investigator
Facility:
Name:
Park Nicollet Clinic - Saint Louis Park
Address:
City:
Saint Louis Park
Zip:
55416
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Regions Hospital
Address:
City:
Saint Paul
Zip:
55101
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
United Hospital
Address:
City:
Saint Paul
Zip:
55102
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Essentia Health Sandstone
Address:
City:
Sandstone
Zip:
55072
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Essentia Health Virginia Clinic
Address:
City:
Virginia
Zip:
55792
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Community Hospital of Anaconda
Address:
City:
Anaconda
Zip:
59711
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Billings Clinic Cancer Center
Address:
City:
Billings
Zip:
59101
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-996-2663
Email:
research@billingsclinic.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Bozeman Health Deaconess Hospital
Address:
City:
Bozeman
Zip:
59715
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Benefis Sletten Cancer Institute
Address:
City:
Great Falls
Zip:
59405
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Logan Health Medical Center
Address:
City:
Kalispell
Zip:
59901
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Community Medical Center
Address:
City:
Missoula
Zip:
59804
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Seven Hills
Address:
City:
Henderson
Zip:
89052
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Charleston
Address:
City:
Las Vegas
Zip:
89102
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Fort Apache
Address:
City:
Las Vegas
Zip:
89148
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
Rutgers Cancer Institute of New Jersey
Address:
City:
New Brunswick
Zip:
08903
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
732-235-7356
Investigator:
Last name:
Eugenia Girda
Email:
Principal Investigator
Facility:
Name:
Roswell Park Cancer Institute
Address:
City:
Buffalo
Zip:
14263
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-767-9355
Email:
askroswell@roswellpark.org
Investigator:
Last name:
Ellis G. Levine
Email:
Principal Investigator
Facility:
Name:
Mount Sinai Hospital
Address:
City:
New York
Zip:
10029
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
212-824-7309
Email:
CCTO@mssm.edu
Investigator:
Last name:
Deborah B. Doroshow
Email:
Principal Investigator
Facility:
Name:
Duke University Medical Center
Address:
City:
Durham
Zip:
27710
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
888-275-3853
Investigator:
Last name:
Niharika B. Mettu
Email:
Principal Investigator
Facility:
Name:
Sanford Bismarck Medical Center
Address:
City:
Bismarck
Zip:
58501
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
701-323-5760
Email:
OncologyClinicalTrialsFargo@sanfordhealth.org
Investigator:
Last name:
Daniel Almquist
Email:
Principal Investigator
Facility:
Name:
Sanford Broadway Medical Center
Address:
City:
Fargo
Zip:
58122
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
701-323-5760
Email:
OncologyClinicalTrialsFargo@sanfordhealth.org
Investigator:
Last name:
Daniel Almquist
Email:
Principal Investigator
Facility:
Name:
Sanford Roger Maris Cancer Center
Address:
City:
Fargo
Zip:
58122
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
701-234-6161
Email:
OncologyClinicalTrialsFargo@sanfordhealth.org
Investigator:
Last name:
Daniel Almquist
Email:
Principal Investigator
Facility:
Name:
UH Seidman Cancer Center at UH Avon Health Center
Address:
City:
Avon
Zip:
44011
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-641-2422
Investigator:
Last name:
Alberto J. Montero
Email:
Principal Investigator
Facility:
Name:
UHHS-Chagrin Highlands Medical Center
Address:
City:
Beachwood
Zip:
44122
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-641-2422
Email:
CTUReferral@UHhospitals.org
Investigator:
Last name:
Alberto J. Montero
Email:
Principal Investigator
Facility:
Name:
Strecker Cancer Center-Belpre
Address:
City:
Belpre
Zip:
45714
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Aultman Health Foundation
Address:
City:
Canton
Zip:
44710
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
330-363-7274
Email:
ClinicalReserachDept@aultman.com
Investigator:
Last name:
Sunitha Vemulapalli
Email:
Principal Investigator
Facility:
Name:
Adena Regional Medical Center
Address:
City:
Chillicothe
Zip:
45601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-779-7585
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Case Western Reserve University
Address:
City:
Cleveland
Zip:
44106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-641-2422
Email:
CTUReferral@UHhospitals.org
Investigator:
Last name:
Alberto J. Montero
Email:
Principal Investigator
Facility:
Name:
Mount Carmel East Hospital
Address:
City:
Columbus
Zip:
43213
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
The Mark H Zangmeister Center
Address:
City:
Columbus
Zip:
43219
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Dayton Physician LLC - Englewood
Address:
City:
Dayton
Zip:
45415
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Kettering Medical Center
Address:
City:
Kettering
Zip:
45429
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Fairfield Medical Center
Address:
City:
Lancaster
Zip:
43130
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Memorial Hospital
Address:
City:
Marysville
Zip:
43040
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
UH Seidman Cancer Center at Lake Health Mentor Campus
Address:
City:
Mentor
Zip:
44060
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-641-2422
Email:
CTUReferral@UHhospitals.org
Investigator:
Last name:
Alberto J. Montero
Email:
Principal Investigator
Facility:
Name:
Knox Community Hospital
Address:
City:
Mount Vernon
Zip:
43050
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Licking Memorial Hospital
Address:
City:
Newark
Zip:
43055
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Mercy Health Perrysburg Cancer Center
Address:
City:
Perrysburg
Zip:
43551
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Southern Ohio Medical Center
Address:
City:
Portsmouth
Zip:
45662
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Springfield Regional Cancer Center
Address:
City:
Springfield
Zip:
45504
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Springfield Regional Medical Center
Address:
City:
Springfield
Zip:
45504
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Mercy Health - Saint Anne Hospital
Address:
City:
Toledo
Zip:
43623
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Saint Ann's Hospital
Address:
City:
Westerville
Zip:
43081
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
Genesis Healthcare System Cancer Care Center
Address:
City:
Zanesville
Zip:
43701
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-488-2745
Email:
Jeffh@columbusccop.org
Investigator:
Last name:
William A. Wilson
Email:
Principal Investigator
Facility:
Name:
University of Oklahoma Health Sciences Center
Address:
City:
Oklahoma City
Zip:
73104
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
405-271-8777
Email:
ou-clinical-trials@ouhsc.edu
Investigator:
Last name:
Adanma Anji Ayanambakkam Attanathi
Email:
Principal Investigator
Facility:
Name:
Providence Newberg Medical Center
Address:
City:
Newberg
Zip:
97132
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Ontario
Address:
City:
Ontario
Zip:
97914
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Providence Willamette Falls Medical Center
Address:
City:
Oregon City
Zip:
97045
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
Providence Portland Medical Center
Address:
City:
Portland
Zip:
97213
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
Providence Saint Vincent Medical Center
Address:
City:
Portland
Zip:
97225
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
UPMC Altoona
Address:
City:
Altoona
Zip:
16601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
protocols@swog.org
Investigator:
Last name:
Haider S. Mahdi
Email:
Principal Investigator
Facility:
Name:
Bryn Mawr Hospital
Address:
City:
Bryn Mawr
Zip:
19010
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
484-476-2649
Email:
turzoe@mlhs.org
Investigator:
Last name:
Paul B. Gilman
Email:
Principal Investigator
Facility:
Name:
UPMC Hillman Cancer Center Erie
Address:
City:
Erie
Zip:
16505
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-389-5208
Email:
haneydl@upmc.edu
Investigator:
Last name:
Haider S. Mahdi
Email:
Principal Investigator
Facility:
Name:
UPMC Cancer Centers - Arnold Palmer Pavilion
Address:
City:
Greensburg
Zip:
15601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
724-838-1900
Investigator:
Last name:
Haider S. Mahdi
Email:
Principal Investigator
Facility:
Name:
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
Address:
City:
Mechanicsburg
Zip:
17050
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-389-5208
Email:
haneydl@upmc.edu
Investigator:
Last name:
Haider S. Mahdi
Email:
Principal Investigator
Facility:
Name:
Riddle Memorial Hospital
Address:
City:
Media
Zip:
19063
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
484-476-2649
Email:
turzoe@mlhs.org
Investigator:
Last name:
Paul B. Gilman
Email:
Principal Investigator
Facility:
Name:
UPMC Hillman Cancer Center - Monroeville
Address:
City:
Monroeville
Zip:
15146
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-389-5208
Email:
haneydl@upmc.edu
Investigator:
Last name:
Haider S. Mahdi
Email:
Principal Investigator
Facility:
Name:
Paoli Memorial Hospital
Address:
City:
Paoli
Zip:
19301
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
484-476-2649
Email:
turzoe@mlhs.org
Investigator:
Last name:
Paul B. Gilman
Email:
Principal Investigator
Facility:
Name:
Thomas Jefferson University Hospital
Address:
City:
Philadelphia
Zip:
19107
Country:
United States
Status:
Not yet recruiting
Contact:
Last name:
Site Public Contact
Phone:
215-600-9151
Email:
ONCTrialNow@jefferson.edu
Investigator:
Last name:
Babar Bashir
Email:
Principal Investigator
Facility:
Name:
University of Pittsburgh Cancer Institute (UPCI)
Address:
City:
Pittsburgh
Zip:
15232
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-647-8073
Investigator:
Last name:
Haider S. Mahdi
Email:
Principal Investigator
Facility:
Name:
UPMC-Passavant Hospital
Address:
City:
Pittsburgh
Zip:
15237
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-367-6454
Investigator:
Last name:
Haider S. Mahdi
Email:
Principal Investigator
Facility:
Name:
Lankenau Medical Center
Address:
City:
Wynnewood
Zip:
19096
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
484-476-2649
Email:
turzoe@mlhs.org
Investigator:
Last name:
Paul B. Gilman
Email:
Principal Investigator
Facility:
Name:
Rapid City Regional Hospital
Address:
City:
Rapid City
Zip:
57701
Country:
United States
Status:
Active, not recruiting
Facility:
Name:
Sanford Cancer Center Oncology Clinic
Address:
City:
Sioux Falls
Zip:
57104
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
605-312-3320
Email:
OncologyClinicTrialsSF@sanfordhealth.org
Investigator:
Last name:
Daniel Almquist
Email:
Principal Investigator
Facility:
Name:
Sanford USD Medical Center - Sioux Falls
Address:
City:
Sioux Falls
Zip:
57117-5134
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
605-312-3320
Email:
OncologyClinicalTrialsSF@SanfordHealth.org
Investigator:
Last name:
Daniel Almquist
Email:
Principal Investigator
Facility:
Name:
M D Anderson Cancer Center
Address:
City:
Houston
Zip:
77030
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-632-6789
Email:
askmdanderson@mdanderson.org
Investigator:
Last name:
Funda Meric-Bernstam
Email:
Principal Investigator
Facility:
Name:
University of Virginia Cancer Center
Address:
City:
Charlottesville
Zip:
22908
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
434-243-6303
Email:
uvacancertrials@hscmail.mcc.virginia.edu
Investigator:
Last name:
Matthew J. Reilley
Email:
Principal Investigator
Facility:
Name:
Inova Schar Cancer Institute
Address:
City:
Fairfax
Zip:
22031
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
703-720-5210
Email:
Stephanie.VanBebber@inova.org
Investigator:
Last name:
Timothy L. Cannon
Email:
Principal Investigator
Facility:
Name:
Inova Fairfax Hospital
Address:
City:
Falls Church
Zip:
22042
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
703-208-6650
Email:
Stephanie.VanBebber@inova.org
Investigator:
Last name:
Timothy L. Cannon
Email:
Principal Investigator
Facility:
Name:
Virginia Cancer Institute
Address:
City:
Richmond
Zip:
23229
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
804-287-3000
Email:
smoore@vacancer.com
Investigator:
Last name:
Andrew Poklepovic
Email:
Principal Investigator
Facility:
Name:
VCU Massey Cancer Center at Stony Point
Address:
City:
Richmond
Zip:
23235
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
ctoclinops@vcu.edu
Investigator:
Last name:
Andrew Poklepovic
Email:
Principal Investigator
Facility:
Name:
Virginia Commonwealth University/Massey Cancer Center
Address:
City:
Richmond
Zip:
23298
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
CTOclinops@vcu.edu
Investigator:
Last name:
Andrew Poklepovic
Email:
Principal Investigator
Facility:
Name:
Carilion Clinic Gynecological Oncology
Address:
City:
Roanoke
Zip:
24016
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
540-985-8510
Investigator:
Last name:
Andrew Poklepovic
Email:
Principal Investigator
Facility:
Name:
VCU Community Memorial Health Center
Address:
City:
South Hill
Zip:
23970
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
nemer.elmouallem@vcuhealth.org
Investigator:
Last name:
Andrew Poklepovic
Email:
Principal Investigator
Facility:
Name:
Swedish Cancer Institute-Edmonds
Address:
City:
Edmonds
Zip:
98026
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
206-215-3086
Email:
PCRC-NCORP@Swedish.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
Swedish Cancer Institute-Issaquah
Address:
City:
Issaquah
Zip:
98029
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
206-215-3086
Email:
PCRC-NCORP@Swedish.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
Valley Medical Center
Address:
City:
Renton
Zip:
98055
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
425-228-3440
Email:
research@valleymed.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
Swedish Medical Center-First Hill
Address:
City:
Seattle
Zip:
98122
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
206-215-3086
Email:
PCRC-NCORP@Swedish.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
Address:
City:
Yakima
Zip:
98902
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
509-574-3535
Email:
Memorial-ClinicalTrials@yvmh.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
Duluth Clinic Ashland
Address:
City:
Ashland
Zip:
54806
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Southern Lakes VLCC
Address:
City:
Burlington
Zip:
53105
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora Saint Luke's South Shore
Address:
City:
Cudahy
Zip:
53110
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora Health Care Germantown Health Center
Address:
City:
Germantown
Zip:
53022
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Grafton
Address:
City:
Grafton
Zip:
53024
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora BayCare Medical Center
Address:
City:
Green Bay
Zip:
54311
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Kenosha South
Address:
City:
Kenosha
Zip:
53142
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Gundersen Lutheran Medical Center
Address:
City:
La Crosse
Zip:
54601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
608-775-2385
Email:
cancerctr@gundersenhealth.org
Investigator:
Last name:
Kurt Oettel
Email:
Principal Investigator
Facility:
Name:
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Address:
City:
Madison
Zip:
53718
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-622-8922
Email:
clinicaltrials@cancer.wisc.edu
Investigator:
Last name:
Nataliya V. Uboha
Email:
Principal Investigator
Facility:
Name:
University of Wisconsin Carbone Cancer Center - University Hospital
Address:
City:
Madison
Zip:
53792
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-622-8922
Email:
clinicaltrials@cancer.wisc.edu
Investigator:
Last name:
Nataliya V. Uboha
Email:
Principal Investigator
Facility:
Name:
Aurora Bay Area Medical Group-Marinette
Address:
City:
Marinette
Zip:
54143
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Milwaukee
Address:
City:
Milwaukee
Zip:
53209
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora Saint Luke's Medical Center
Address:
City:
Milwaukee
Zip:
53215
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora Sinai Medical Center
Address:
City:
Milwaukee
Zip:
53233
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Vince Lombardi Cancer Clinic - Oshkosh
Address:
City:
Oshkosh
Zip:
54904
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Racine
Address:
City:
Racine
Zip:
53406
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Vince Lombardi Cancer Clinic-Sheboygan
Address:
City:
Sheboygan
Zip:
53081
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora Medical Center in Summit
Address:
City:
Summit
Zip:
53066
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Vince Lombardi Cancer Clinic-Two Rivers
Address:
City:
Two Rivers
Zip:
54241
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Milwaukee West
Address:
City:
Wauwatosa
Zip:
53226
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Aurora West Allis Medical Center
Address:
City:
West Allis
Zip:
53227
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Antony Ruggeri
Email:
Principal Investigator
Facility:
Name:
Puerto Rico Hematology Oncology Group
Address:
City:
Bayamon
Zip:
00961
Country:
Puerto Rico
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
787-780-2865
Investigator:
Last name:
Luis J. Santos Reyes
Email:
Principal Investigator
Facility:
Name:
Centro Comprensivo de Cancer de UPR
Address:
City:
San Juan
Zip:
00927
Country:
Puerto Rico
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
888-823-5923
Email:
ctsucontact@westat.com
Investigator:
Last name:
Luis J. Santos Reyes
Email:
Principal Investigator
Start date:
September 22, 2023
Completion date:
August 31, 2025
Lead sponsor:
Agency:
National Cancer Institute (NCI)
Agency class:
NIH
Source:
National Cancer Institute (NCI)
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05554380
